168 related articles for article (PubMed ID: 30452719)
1. Pattern of care in adjuvant therapy for resected Stage I non-small cell lung cancer: real-world data from Japan.
Yoh K; Takamochi K; Shukuya T; Hishida T; Tsuboi M; Sakurai H; Goto Y; Yoshida K; Ohde Y; Okumura S; Ohashi Y; Kunitoh H
Jpn J Clin Oncol; 2019 Jan; 49(1):63-68. PubMed ID: 30452719
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC-Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy.
Shukuya T; Takamochi K; Sakurai H; Yoh K; Hishida T; Tsuboi M; Goto Y; Kudo Y; Ohde Y; Okumura S; Taguri M; Kunitoh H
JTO Clin Res Rep; 2022 May; 3(5):100320. PubMed ID: 35601927
[TBL] [Abstract][Full Text] [Related]
3. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
[TBL] [Abstract][Full Text] [Related]
4. Multicenter observational cohort study of post-operative treatment for completely resected non-small-cell lung cancer of pathological Stage I (T1 >2 cm and T2 in TNM classification version 6).
Hishida T; Tsuboi M; Shukuya T; Takamochi K; Sakurai H; Yoh K; Ohashi Y; Kunitoh H
Jpn J Clin Oncol; 2015 May; 45(5):499-501. PubMed ID: 25724215
[TBL] [Abstract][Full Text] [Related]
5. A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
Tsuchiya T; Kamohara R; Muraoka M; Nagayasu T; Saeki S; Takenoyama M; Suzuki M; Inada K; Tokunaga S; Hayashi T; Urabe S; Koga T; Akamine S; Sugio K
BMC Cancer; 2020 Dec; 20(1):1192. PubMed ID: 33276755
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery.
Endo C; Saito Y; Iwanami H; Tsushima T; Imai T; Kawamura M; Kondo T; Koike K; Handa M; Kanno R; Fujimura S;
Lung Cancer; 2003 May; 40(2):181-6. PubMed ID: 12711119
[TBL] [Abstract][Full Text] [Related]
7. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG).
Wada H; Miyahara R; Tanaka F; Hitomi S
Eur J Cardiothorac Surg; 1999 Apr; 15(4):438-43. PubMed ID: 10371118
[TBL] [Abstract][Full Text] [Related]
8. A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non-small cell lung cancer (JCOG 0707).
Kunitoh H; Tsuboi M; Wakabayashi M; Okada M; Suzuki K; Watanabe SI; Asamura H;
JTCVS Open; 2020 Dec; 4():90-102. PubMed ID: 36004301
[TBL] [Abstract][Full Text] [Related]
9. Oral uracil-tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early-stage non-small cell lung cancer patients.
Liang SK; Wu CW; Chang CI; Keng LT; Lee MR; Wang JY; Ko JC; Liao WY; Chen KY; Ho CC; Shih JY; Yu CJ
Cancer Med; 2023 Sep; 12(17):17993-18004. PubMed ID: 37559409
[TBL] [Abstract][Full Text] [Related]
10. Postoperative adjuvant therapy for completely resected early-stage non-small cell lung cancer.
Kato H; Tsuboi M; Kato Y; Ikeda N; Okunaka T; Hamada C
Int J Clin Oncol; 2005 Jun; 10(3):157-64. PubMed ID: 15990962
[TBL] [Abstract][Full Text] [Related]
11. Is adjuvant chemotherapy for completely resected p-stage IA (>2 cm) and stage IB non-small-cell lung cancer beneficial for elderly patients? A large, retrospective cohort study based on real-world data from Japan.
Adachi H; Saito A; Shintani Y; Okami J; Ito H; Ohtsuka T; Mori T; Watanabe SI; Chida M; Endo S; Nakanishi R; Kadokura M; Suzuki H; Miyaoka E; Yoshino I; Date H; Japanese Joint Committee Of Lung Cancer Registry
Jpn J Clin Oncol; 2023 Dec; 53(12):1191-1200. PubMed ID: 37626449
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study.
Nakagawa M; Tanaka F; Tsubota N; Ohta M; Takao M; Wada H;
Ann Oncol; 2005 Jan; 16(1):75-80. PubMed ID: 15598942
[TBL] [Abstract][Full Text] [Related]
13. A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer.
Tsuboi M; Kondo K; Takizawa H; Kawakita N; Sawada T; Toba H; Kawakami Y; Yoshida M; Ishikura H; Kimura S; Tangoku A
J Med Invest; 2018; 65(1.2):90-95. PubMed ID: 29593202
[TBL] [Abstract][Full Text] [Related]
14. A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer.
Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Tada H; Kajiwara S; Watanabe N; Okada M; Sakamoto J; Aoe M; Soh J; Miyoshi S; Hotta K; Matsuo K; Date H
J Thorac Oncol; 2018 May; 13(5):699-706. PubMed ID: 29505900
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy for completely resected non-small-cell lung cancer.
Suehisa H; Toyooka S
Acta Med Okayama; 2009 Oct; 63(5):223-30. PubMed ID: 19893597
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).
Yamaguchi M; Tada H; Mitsudomi T; Seto T; Yokoi K; Katakami N; Nakagawa K; Oda M; Ohta M; Sawa T; Yamashita M; Iked N; Saka H; Higashiyama M; Nomori H; Semba H; Negoro S; Chiba Y; Shimokawa M; Fukuoka M; Nakanishi Y;
Int J Clin Oncol; 2021 Dec; 26(12):2216-2223. PubMed ID: 34463869
[TBL] [Abstract][Full Text] [Related]
17. Alpha-actinin-4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas.
Noro R; Honda K; Nagashima K; Motoi N; Kunugi S; Matsubayashi J; Takeuchi S; Shiraishi H; Okano T; Kashiro A; Meng X; Yoshida Y; Watanabe S; Usuda J; Inoue T; Wilber H; Ikeda N; Seike M; Gemma A; Kubota K
Cancer Sci; 2022 Mar; 113(3):1002-1009. PubMed ID: 34845792
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of ground-glass areas within tumours in non-small-cell lung cancer.
Sakurai H; Goto Y; Yoh K; Takamochi K; Shukuya T; Hishida T; Tsuboi M; Yoshida K; Ohde Y; Okumura S; Taguri M; Kunitoh H
Eur J Cardiothorac Surg; 2024 Mar; 65(4):. PubMed ID: 38598462
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer.
Hamada C; Tanaka F; Ohta M; Fujimura S; Kodama K; Imaizumi M; Wada H
J Clin Oncol; 2005 Aug; 23(22):4999-5006. PubMed ID: 16051951
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.
Kato H; Ichinose Y; Ohta M; Hata E; Tsubota N; Tada H; Watanabe Y; Wada H; Tsuboi M; Hamajima N; Ohta M;
N Engl J Med; 2004 Apr; 350(17):1713-21. PubMed ID: 15102997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
